Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.

Leukemia & lymphoma - 1 Jan 2015

Awan Farrukh T, Flynn Joseph M, Jones Jeffrey A, Andritsos Leslie A, Maddocks Kami J, Sass Ellen J, Lucas Margaret S, Chase Weihong, Waymer Sharon, Ling Yonghua, Jiang Yao, Phelps Mitch A, Byrd John C, Lucas David M, Woyach Jennifer A

Abstract excerpt

The proteasome complex degrades proteins involved in a variety of cellular processes and is a powerful therapeutic target in several malignancies. Carfilzomib is a potent proteasome inhibitor which induces rapid chronic lymphocytic leukemia (CLL) cell apoptosis in vitro. We conducted a phase I dose-escalation trial to determine the safety and tolerability of carfilzomib in relapsed/refractory CLL or small...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosome Aberrations
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Immunoglobulin Heavy Chains

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Maximum Tolerated Dose

Share to Oligopeptides

Share to Proteasome Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 25669927
DOI: 10.3109/10428194.2015.1014368
PMCID: PMC4835239

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.PMID 25669927Read ↗

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.Semantic proximity Read ↗

Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.Semantic proximity Read ↗

Orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients: Multi-center, Single-arm, Open-label, Phase 2 StudySemantic proximity Read ↗

Antibody therapy for chronic lymphocytic leukemia.Semantic proximity Read ↗

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.Semantic proximity Read ↗

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.Semantic proximity Read ↗

Gene Immunotherapy of Chronic Lymphocytic Leukemia: A Phase I Study of Intranodally Injected Adenovirus Expressing a Chimeric CD154 MoleculeSemantic proximity Read ↗

Mucin 20 modulates proteasome capacity through c‐Met signalling to increase carfilzomib sensitivity in mantle cell lymphomaSemantic proximity Read ↗

Novel Proteasome Inhibitors to Overcome Bortezomib ResistanceSemantic proximity Read ↗

Small Molecule Inhibitors of Wnt/β-Catenin/Lef-1 Signaling Induces Apoptosis in Chronic Lymphocytic Leukemia Cells In Vitro and In VivoSemantic proximity Read ↗

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.Semantic proximity Read ↗

Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.